INTANGIBLE ASSETS AND GOODWILL (Details) (USD $)																								3 Months Ended
	Sep. 30, 2013		Dec. 31, 2012		Sep. 30, 2013 Product brands	Dec. 31, 2012 Product brands	Sep. 30, 2013 Corporate brands	Dec. 31, 2012 Corporate brands	Sep. 30, 2013 Product rights	Dec. 31, 2012 Product rights	Sep. 30, 2013 Partner relationships	Dec. 31, 2012 Partner relationships	Sep. 30, 2013 Out-licensed technology and other	Dec. 31, 2012 Out-licensed technology and other	Sep. 30, 2013 In Process Research and Development [Member]		Dec. 31, 2012 In Process Research and Development [Member]		Sep. 30, 2013 Corporate brands		Aug. 05, 2013 Corporate brands	Dec. 31, 2012 Corporate brands		Sep. 30, 2013 Non-recurring basis Amortization and Impairments of Finite-lived Intangible Assets Developed Markets Ezogabine Retigabine	Sep. 30, 2013 Non-recurring basis Amortization and Impairments of Finite-lived Intangible Assets Developed Markets Discontinued OTC Skincare [Member]	Mar. 31, 2013 Non-recurring basis Amortization and Impairments of Finite-lived Intangible Assets Developed Markets Opana	Sep. 30, 2012 Non-recurring basis In-process Research and Development Impairments and Other Charges In Process Research and Development [Member]	Sep. 30, 2013 Non-recurring basis In-process Research and Development Impairments and Other Charges Ezogabine Retigabine In Process Research and Development [Member]	Sep. 30, 2013 Non-recurring basis In-process Research and Development Impairments and Other Charges Lacrisert In Process Research and Development [Member]	Sep. 30, 2012 Non-recurring basis In-process Research and Development Impairments and Other Charges IDP-107 program In Process Research and Development [Member]	Sep. 30, 2013 Non-recurring basis In-process Research and Development Impairments and Other Charges Developed Markets Ezogabine Retigabine
Finite-lived intangible assets:
Gross Carrying Amount	$ 14,022,262,000	[1]	$ 10,759,419,000	[1]	$ 10,199,918,000	$ 7,968,318,000	$ 363,482,000	$ 284,287,000	$ 3,013,321,000	$ 2,110,350,000	$ 190,489,000	$ 187,012,000	$ 255,052,000	$ 209,452,000
Accumulated Amortization	(3,469,849,000)	[1]	(1,997,626,000)	[1]	(2,470,281,000)	(1,345,367,000)	(38,413,000)	(25,336,000)	(811,998,000)	(525,186,000)	(73,043,000)	(44,230,000)	(76,114,000)	(57,507,000)
Net Carrying Amount	10,552,413,000	[1]	8,761,793,000	[1]	7,729,637,000	6,622,951,000	325,069,000	258,951,000	2,201,323,000	1,585,164,000	117,446,000	142,782,000	178,938,000	151,945,000
Indefinite-lived intangible assets:
Indefinite-lived intangible assets															847,375,000	[2]	546,876,000	[2]	1,690,551,000	[3]	1,690,551,000	0	[3]
Total intangible assets
Gross carrying amount	16,560,188,000		11,306,295,000
Net Carrying Amount	13,090,339,000		9,308,669,000
Impairment charges on intangible assets																								551,600,000	10,000,000	22,200,000		93,800,000	27,300,000	133,400,000	93,800,000
Payment to terminate research and development commitment																											$ 12,000,000

[1] In the first quarter of 2013, the Company recognized a write-off of $22.2 million related to Opana®, a pain relief medication approved in Canada (included in the Company's Developed Markets segment), due to production issues arising in the first quarter of 2013. These production issues resulted in higher spending projections and delayed commercialization timelines which, in turn, triggered the Company’s decision to suspend its launch plans. The Company does not believe this program has value to a market participant. These impairment charges were recognized in Amortization and impairments of finite-lived intangible assets in the consolidated statements of (loss) income. (2)In the third quarter of 2013, the Company wrote off an IPR&D asset of $93.8 million relating to a modified-release formulation of ezogabine/retigabine. For further information regarding this write-off, see note 7 titled “FAIR VALUE MEASUREMENTS”.In addition, in the third quarter of 2013, the Company wrote-off IPR&D assets of $27.3 million, in the aggregate, due to the write-off of IPR&D assets acquired by Valeant as part of Aton acquisition in May 2010, mainly related to the termination of the A007 (Lacrisert®) development program in the third quarter of 2013. The Company does not believe these programs have value to a market participant.In the third quarter of 2012, the Company recorded charges of (i) $133.4 million related to the write-off of an acquired IPR&D asset related to the IDP-107 dermatology program, which was acquired in September 2010 as part of merger between the Company (then named Biovail Corporation (“Biovail”)) and Valeant, and (ii) $12.0 million related to a payment to terminate a research and development commitment with a third party. Through discussion with various internal and external Key Opinion Leaders, the Company completed its analysis of the Phase 2 study results for IDP-107 during the third quarter of 2012. This led to the Company’s decision in the third quarter of 2012 to terminate the program and fully impair the asset. As attempts to identify a partner for the program were not successful, the Company does not believe the program has value to a market participant. The write-offs of the IPR&D assets were recorded in In-process research and development impairments and other charges in the consolidated statements of (loss) income. For further information regarding asset impairment charges, see note 7 titled “FAIR VALUE MEASUREMENTS”.(3)Represents the B&L corporate trademark, which has an indefinite useful life and is not amortizable. See note 3 “BUSINESS COMBINATIONS” for further information.

[2] Effective in the first quarter of 2013, the Company has two reportable segments: Developed Markets and Emerging Markets. Accordingly, the Company has restated prior period segment information to conform to the current period presentation. For further details, see note 20 titled “SEGMENT INFORMATION”.

[3] Primarily relates to the B&L, Obagi and Natur Produkt acquisitions (as described in note 3).